By Fineline Cube 
The European Commission (EC) granted marketing authorization this week for Bristol-Myers Squibb‘s (BMS, NYSE: BMY) Sotyktu (deucravacitinib) for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. The approval covers both monotherapy and combination use with methotrexate, following U.S. FDA clearance for the same indication in March 2026.
Regulatory Approval Details
| Parameter | Detail |
|---|---|
| Drug | Sotyktu (deucravacitinib) |
| Mechanism | Oral TYK2 inhibitor with allosteric inhibition |
| Indication | Active psoriatic arthritis (PsA) |
| Patient Population | Adults with inadequate response or intolerance to prior DMARD therapy |
| Regimen | Monotherapy or combination with methotrexate |
| Regulatory Milestones | FDA approval (March 2026), EC approval (May 2026) |
This dual regulatory approval establishes Sotyktu as a new treatment option for PsA patients across major global markets.
Mechanism of Action & Scientific Innovation
Sotyktu represents a first-in-class oral TYK2 inhibitor with a unique mechanism distinguishing it from traditional JAK inhibitors:
- Allosteric Inhibition: Binds to the regulatory domain of TYK2 rather than the catalytic domain
- Selective Cytokine Blockade: Specifically inhibits signaling of IL-23, IL-12, and type I interferons (IFN)
- Pathogenic Relevance: These cytokines are key drivers in the pathogenesis of both psoriasis and psoriatic arthritis
- Safety Profile: Allosteric approach potentially offers improved selectivity and reduced off-target effects compared to pan-JAK inhibitors
The targeted inhibition of this specific cytokine axis addresses the underlying inflammatory pathways in PsA while potentially avoiding broader immunosuppressive effects.
Market & Commercial Context
- PsA Treatment Gap: Approximately 30-40% of psoriasis patients develop PsA, representing a significant unmet need for effective, well-tolerated oral therapies
- Competitive Landscape: Sotyktu enters a market dominated by biologics (TNF inhibitors, IL-17/23 inhibitors) and conventional DMARDs, offering the convenience of oral administration
- Dual Indication Strategy: Already approved for plaque psoriasis, Sotyktu now expands into PsA, leveraging established brand recognition and physician familiarity
- Global Rollout: U.S. and EU approvals position BMS for rapid international commercial launch, with additional regulatory submissions pending in other regions
- Revenue Potential: Analysts project peak annual sales of $2-3 billion across both psoriasis and PsA indications
This approval strengthens BMS’s immunology portfolio and provides physicians with a novel oral option for managing the complex inflammatory pathways driving psoriatic disease.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and market opportunities. Actual results may differ due to risks including competitive dynamics, market adoption rates, safety findings, and regulatory decisions in other jurisdictions.-Fineline Info & Tech